Obesity inhibits chemotherapy efficacy by inducing inflammation and connective tissue hyperplasia in pancreatic cancer (Incio et al., 2016), enhancing MVP protein expression in breast cancer (Lehuédé et al., 2019), and inducing epithelial mesenchymal transformation in prostate cancer (Su et al., 2019). Here, MVP is linked to obesity due to melanocortin 4 receptor deficiency.